b.well Connected Health and myTomorrows have announced a partnership focused on improving how patients are identified and connected to clinical trials through the integration of unified health records and AI-powered matching technology. The collaboration is intended to help pharmaceutical sponsors and trial sites identify eligible patients more efficiently while reducing barriers that often delay or prevent participation in clinical research.
Under the agreement, b.well will contribute its FHIR-based platform, which aggregates and standardizes health data from nearly 2.4 million providers, more than 330 health plans, state health information exchanges, laboratories, pharmacies, and more than 350 wearable devices and biomarkers. The platform creates longitudinal patient records designed to support AI-enabled healthcare applications.
myTomorrows will integrate its AI-powered clinical trial pre-screening and matching technology into the workflow. The combined platform is expected to automate parts of the eligibility matching process, reducing the need for repeated data collection and helping patients and clinicians identify relevant trial opportunities earlier in the care journey.
Kristen Valdes, Founder and CEO of b.well, said, “I know firsthand that a patient and their family will move mountains to access a clinical trial that could change their outcome. But the system hasn't been set up to allow that.”
She added, “Through this collaboration, patients have the power to choose to share their data to find out if there is a trial that could help them. That's not only good for patients, but it is how we diversify trials and get new drugs to market faster. That's what this partnership makes possible, and it reflects everything b.well was built to do.”
The companies said the partnership also addresses broader industry priorities, including improving diversity in clinical trials, reducing recruitment timelines, and lowering administrative overhead associated with traditional enrollment processes. The integration reflects increasing use of real-time health data and AI technologies to support faster and more coordinated clinical decision-making.
Michel van Harten, MD, CEO at myTomorrows, said, “By combining our clinical trial matching expertise with b.well's ability to unify and activate patient health data, we can reach more patients, in more communities, and remove the friction that has historically kept them from accessing emerging treatments.”
He added, “This partnership opens a new chapter in how the industry approaches clinical trial recruitment at scale.”
Click here for the original news story.
